Anti-tumour effect of tocilizumab for osteosarcoma cell lines

AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Sao...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagi, Tomohito, Nakamura, Tomoki, Kita, Kouji, Iino, Takahiro, Asanuma, Kunihiro, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672325/
https://www.ncbi.nlm.nih.gov/pubmed/33179539
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672325/
https://www.ncbi.nlm.nih.gov/pubmed/33179539
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1

Ejemplares similares